登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688185 证券简称：康希诺 公告编号：2025-032 康希诺生物股份公司 第三届监事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 康希诺生物股份公司（以下简称"公司"）第三届监事会第十次会议于2025年10月27日在公司会议室以现 场及通讯的方式召开。会议通知已于会议召开5日前以电子邮件形式送达全体监事。本次会议由监事会 主席肖治召集，应到监事3人，实到监事3人。会议的召集、召开和表决程序符合《中华人民共和国公司 法》（以下简称"《公司法》"）等法律法规及规范性文件和《康希诺生物股份公司章程》（以下简 称"《公司章程》"）的规定，合法有效。 二、监事会会议审议情况 经与会监事审议，逐项表决，形成决议如下： （一）《关于取消监事会、修订〈公司章程〉及其附件并办理工商变更登记的议案》 监事会认为：本事项符合《公司法》《关于新〈公司法〉配套制度规则实施相关过渡期安排》等相关法 律法规、规范性文件的规定，同意不再设置监 ...

Core Insights - The company reported a revenue of 693 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.13% [1] - The net profit attributable to the parent company was 14.44 million yuan, marking a turnaround from a loss to profit year-on-year [1] - The non-deductible net profit showed a loss of 82.86 million yuan, indicating ongoing challenges in core operations [1] - The basic earnings per share stood at 0.06 yuan [1]

Major Events - Guizhou Moutai's chairman Zhang Deqin resigned due to work adjustments, with Chen Hua recommended as the new chairman [4] - Kid King plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [5] - Postal Savings Bank received approval to establish a financial asset investment company with a registered capital of 10 billion RMB [6] - Seres announced that the maximum price for its H-share issuance will not exceed 131.5 HKD per share [7] - China Bank appointed Liu Chenggang as vice president [8] - ST Guangwu's stock will be delisted from risk warning and renamed to "Guanghui Logistics" [9] - Wireless Media's initial pricing for share transfer is set at 29.11 RMB per share [10] - Jiangshan Oupai's subsidiaries in Henan and Chongqing will cease operations due to insufficient orders and will transfer business to Zhejiang [11][12] - Zhenyu Technology plans to invest 2.11 billion RMB in precision component manufacturing and humanoid robot projects [13] - Jinyuan Co.'s general manager Lian Changyun resigned, with Qiu Yongping appointed as the new general manager [14] Performance Overview - CanSino reported a Q3 net profit of 27.93 million RMB, up 842.01% year-on-year [15] - Jiangshan Co. achieved a Q3 net profit of 86.73 million RMB, a significant increase of 11,890.01% year-on-year [16] - Yingshi Innovation's Q3 net profit decreased by 15.90% to 272 million RMB [17] - Chip Origin reported a Q3 net loss of 26.85 million RMB [18] - Tonghua Dongbao's Q3 net profit surged by 499.86% to 984 million RMB [19] - Hengrui Medicine's Q3 net profit increased by 9.53% to 1.301 billion RMB [20] - Zhongguang Lightning's Q3 net profit rose by 382.66% to 6.46 million RMB [21] - Ice River Network's Q3 net profit grew by 244.58% to 166 million RMB [22] - Daheng Technology's Q3 net profit skyrocketed by 1,960.72% to 71.48 million RMB [23] - Yanjin Puzhi's Q3 net profit increased by 33.55% to 232 million RMB [24] - Sichuan Gold's Q3 net profit reached 160 million RMB, up 184.38% year-on-year [26] - Sanbo Brain Science's Q3 net profit fell by 63.26% to 13.93 million RMB [27] - Hengli Petrochemical's Q3 net profit rose by 81.47% to 1.972 billion RMB [28] - Deepin Technology's Q3 net profit surged by 1,097.40% to 147 million RMB [29] - Huisheng Biological's Q3 net profit increased by 1,575.79% to 70.72 million RMB [30] - Gaode Infrared's Q3 net profit grew by 1,143.72% to 401 million RMB [31] - Qingdao Beer reported a Q3 net profit of 1.37 billion RMB, up 1.62% [32] - Nanjing Public Utilities' Q3 net profit soared by 2,492.12% to 84.62 million RMB [34] - Zhangyuan Tungsten's Q3 net profit increased by 118.56% to 75.02 million RMB [35] - Yongmaotai's Q3 net profit rose by 6,319.92% to 30.41 million RMB [36] - Northern Rare Earth's Q3 net profit increased by 69.48% to 610 million RMB [37] - Hunan Gold's Q3 net profit grew by 63.13% to 373 million RMB [38] - Wansheng Intelligent's Q3 net profit increased by 205.56% to 67.13 million RMB [39] - Saiwei Electronics reported a Q3 net profit of 1.576 billion RMB, up 2,199.10% [40] Financing Activities - Lingzhi Software is planning to acquire control of Kaimiride and raise matching funds [41] Major Contracts - High-speed Rail Electric has pre-qualified for a 62.39 million RMB urban rail transit project [42]

Group 1 - The core point of the article is that CanSino Biologics (06185.HK) announced the resignation of independent non-executive directors Gui Shuifa and Liu Jianzhong due to the expiration of their six-year term [1] - The company has nominated Zuo Min and Ji Xuefeng as candidates for independent non-executive directors for the third board, pending approval by shareholders at an extraordinary general meeting [1]

Core Viewpoint - The A-share and Hong Kong stock pharmaceutical sectors have shown significant structural differentiation in 2023, with the innovative drug sector recovering in valuation due to policy relaxation and global collaboration, while the vaccine sub-sector lags behind due to price wars and a shrinking infant vaccination population [1][2]. Industry Analysis - The vaccine industry is at a critical juncture of "pain and opportunity," facing traditional price competition that squeezes profit margins, while high-end products and new market segments (like adult and overseas markets) are emerging as potential growth paths for companies with technological barriers [1][3]. - The vaccine sector is undergoing a "pressure test" in 2024, with a significant decline in revenue and profit due to homogenized competition, but signs of recovery are emerging as the sector shows a 20% quarter-on-quarter revenue growth in Q2 2025 [4][5]. Company Analysis - CanSino Biologics, a company with both innovative and commercial capabilities in the domestic vaccine sector, has been undervalued by the market, which still perceives it as a "single-product biotech" despite its comprehensive breakthroughs in commercialization, finance, pipeline, and globalization [1][10]. - CanSino's Q3 2025 financial report shows a revenue of approximately 693 million yuan, a year-on-year increase of 22.13%, and a net profit of approximately 14.44 million yuan, indicating a successful turnaround and enhanced profitability [11][12]. - The company has developed a unique four-valent meningococcal vaccine, which is the only one approved in China, and is expanding its market reach by increasing the age range for vaccination, thus raising its market ceiling [11]. - CanSino's cash flow from operating activities reached 33.49 million yuan, indicating strengthened self-sustaining capabilities that provide funding for pipeline advancement [12]. - The company has built five major technology platforms that create core barriers, supporting a diverse pipeline of innovative vaccines targeting various diseases, including a recently approved 13-valent pneumococcal polysaccharide conjugate vaccine [13][14]. - CanSino's internationalization strategy, which includes local production and technology output, is expected to unlock significant overseas market potential, particularly in regions like Southeast Asia and the Middle East [16][17].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 海外監管公告 本 公 告 乃 康 希 諾 生 物 股 份 公 司（「本公司」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市規則第13.10B條而發表。 茲 載 列 本 公 司 於 上 海 證 券 交 易 所 網 站 刊 發 的《康 希 諾 生 物 股 份 公 司 第 三 屆 監 事 會 第 十 次 會 議 決 議 公 告》《康 希 諾 生 物 股 份 公 司 關 於 取 消 監 事 會、修 訂<公司章程> 及 其 附 件 並 辦 理 工 商 變 更 登 記 的 公 告》《康 希 諾 生 物 股 份 公 司 關 於 獨 立 非 執 行 董 事辭任並選舉獨立非執行董事的公告》《康希諾生物股份公司關於調整2025年A 股限制性股票激勵計劃相關事項的公告》《 ...

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 董事會薪酬與考核委員會工作細則 第一章 總 則 第一條 為 進 一 步 建 立 健 全 康 希 諾 生 物 股 份 公 司（以 下 簡 稱「公 司」）薪 酬 與 考 核 管 理 制 度，完 善 公 司 治 理 結 構，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公司 法》」）《上 海 證 券 交 易 所 科 創 板 股 票 上 市 規 則》（以 下 簡 稱「《科創板上市規則》」）《上 海證券交易所科創板上市公司自律監管指引第1號––規 範 運 作》（以 下 簡 稱「《科創 板規範運作》」）《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《香港上市 規則》」）等 相 關 法 律、法 規、規 範 性 文 件 及 當 前 適 用 的《康 希 諾 生 物 股 份 公 司 章 程》 （以 下 簡 稱「《公司章程》」），公 司 特 設 立 董 事 會（以 下 簡 稱「董事會」）薪 酬 與 考 核 委 員 會，並 結 合 公 司 實 際，制 定 本《康 ...

Core Viewpoint - 康希诺 reported a significant increase in revenue and a return to profitability in the first three quarters of 2025, driven by strong market performance of its innovative vaccine products and enhanced government support [1] Financial Performance - The company achieved an operating income of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to the company was 14.44 million yuan, marking a turnaround from previous losses [1] Product and Market Development - 曼海欣, as one of the only four-valent meningococcal conjugate vaccines in China, has shown strong market performance and increasing market share [1] - The growth in sales revenue contributed to the year-on-year increase in operating income from the beginning of the year to the reporting period [1] Research and Development Support - The company has accelerated its R&D projects and international collaborations, leading to increased government grants and international funding, resulting in a year-on-year increase of 233.63% in recognized other income [1] Profitability and Cost Management - The overall gross profit margin for the reporting period was 80.67%, an increase of 6.47 percentage points year-on-year [1] - The company has implemented cost reduction and efficiency improvement measures, achieving savings in multiple expense categories during the reporting period [1]

CanSino Biologics Inc. 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） 董事會提名委員會工作細則 第一章 總 則 第一條 為 規 範 康 希 諾 生 物 股 份 公 司（以 下 簡 稱「公 司」）董 事 及 高 級 管 理 人 員 的 產 生，優 化 董 事 會 組 成，完 善 公 司 治 理 結 構，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公司法》」）《上 海 證 券 交 易 所 科 創 板 股 票 上 市 規 則》（以 下 簡 稱「《科創板上 市規則》」）《上 海 證 券 交 易 所 科 創 板 上 市 公 司 自 律 監 管 指 引 第1號––規 範 運 作》（以 下 簡 稱「《科創板規範運作》」）《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《香港上市規則》」）等 相 關 法 律、法 規、規 範 性 文 件 及《康 希 諾 生 物 股 份 公 司 章 程》（以 下 簡 稱「《公司章程》」），公 司 特 設 立 董 事 會 提 名 委 員 會，並 結 合 公 司 實 際， 制 定 本《康 希 諾 ...

Core Viewpoint - 康希诺生物 reported a significant improvement in financial performance for the first three quarters of 2025, with a notable increase in revenue and a shift from loss to profit [1] Financial Performance - The company achieved an operating revenue of 693 million yuan, representing a year-on-year growth of 22.13% [1] - The net profit attributable to shareholders was 14.44 million yuan, a turnaround from a net loss of 222 million yuan in the same period last year [1] - Basic earnings per share were reported at 0.06 yuan [1]